









Markets
/
Stocks
/
nasdaq-xbit
/

XBiotech Inc

XBIT

2.370USD

+0.070+3.04%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

72.26MMarket Cap

LossP/E TTM



XBiotech Inc

2.370

+0.070+3.04%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of XBiotech Inc

Currency: USD Updated: 2026-02-06

Key Insights

XBiotech Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 215 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.In the medium term, the stock price is expected to remain stable.Despite a weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

XBiotech Inc's Score

Industry at a Glance

Industry Ranking

215 / 392

Overall Ranking

440 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

XBiotech Inc Highlights

StrengthsRisks

XBiotech Inc. is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies for treating a variety of diseases, such as inflammatory conditions like rheumatology, infectious disease, cardiovascular disease and cancer. The Company's True Human monoclonal antibodies are derived from human donors that mount a natural human immune response. The Company is focused on therapies that block a potent substance, known as interleukin-1 alpha (IL-1a), that mediates a number of pathophysiological processes including tissue breakdown (i.e. synovium, cartilage, bone), paraneoplastic angiogenesis and tumor stroma remodeling, formation of blood clots, malaise, muscle wasting and general inflammation. It has various candidate products, including Natrunix. It has a clinical-stage therapeutic for methicillin resistant Staphylococcus aureus (MRSA), and several pre-clinical-stage therapeutics, including an oral delivery antibody therapeutic for colon infection by C. difficile.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 0.00.

Overvalued

The company’s latest PE is -2.48, at a high 3-year percentile range.

Held by The Vanguard

Star Investor The Vanguard holds 299.56K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.31.

Analyst Rating

Based on 0 analysts

Current Rating

Target Price

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of XBiotech Inc is 6.88, ranking 192 out of 392 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is high.

Score

Industry at a Glance

Previous score

6.88

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

4.69

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

4.70

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

5.00

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

XBiotech Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of XBiotech Inc is 7.62, ranking 98 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -2.48, which is -21.98% below the recent high of -1.93 and -306.73% above the recent low of -10.08.

Score

Industry at a Glance

Previous score

7.62

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 215/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

No earnings forecast score is currently available for XBiotech Inc. The Biotechnology & Medical Research industry's average is 8.05.

Score

Industry at a Glance

Previous score

0.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of XBiotech Inc is 5.31, ranking 321 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 2.64 and the support level at 2.19, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

5.10

Change

0.21

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(3)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.072

Neutral

RSI(14)

41.238

Neutral

STOCH(KDJ)(9,3,3)

18.237

Neutral

ATR(14)

0.116

Low Volatility

CCI(14)

-110.670

Sell

Williams %R

79.982

Sell

TRIX(12,20)

-0.034

Sell

StochRSI(14)

58.430

Buy

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

2.392

Sell

MA10

2.505

Sell

MA20

2.542

Sell

MA50

2.486

Sell

MA100

2.511

Sell

MA200

2.724

Sell

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of XBiotech Inc is 3.00, ranking 197 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 12.25%, representing a quarter-over-quarter increase of 52.11%. The largest institutional shareholder is The Vanguard, holding a total of 299.56K shares, representing 0.98% of shares outstanding, with 71.82% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Gut (Thomas)

3.91M

Simard (John)

3.82M

McKenzie (Thorpe W)

2.70M

Millennium Management LLC

416.34K

-24.49%

Kundig (Thomas)

300.00K

The Vanguard Group, Inc.

Star Investors

819.24K

-13.35%

BlackRock Institutional Trust Company, N.A.

252.91K

-19.99%

Geode Capital Management, L.L.C.

221.86K

+0.54%

Waldin (Jan-Paul)

200.24K

RBF Capital, LLC

200.00K

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of XBiotech Inc is 2.62, ranking 216 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 0.87. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. XBiotech Inc’s latest ESG disclosure leads the Biotechnology & Medical Research industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.